Monopar Therapeutics Inc.

NASDAQ:MNPR

Biotechnology

Healthcare
$70.75 +2.45%

+$1.58 today

Market cap
$479.46M
Beta
1.54
P/E (TTM)
-37.6
EPS (TTM)
-$1.76
52W Low $29.18High $105.00

Volume 0.10M

Average 0.17M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$12.20M

FY 2025 · Annual

Investing Cash Flow

-$63.45M

FY 2025 · Annual

Financing Cash Flow

$91.57M

FY 2025 · Annual

+54.4% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(9.1M)(10.52M)(8.4M)(15.59M)(13.72M)
Depreciation & Amortization00000
Deferred Income Tax00000
Stock-Based Compensation1.47M1.64M1.9M1.14M4.84M
Change in Working Capital317.77K1.65M(1.35M)3.49M(2.61M)
Accounts Receivables00000
Inventory00000
Accounts Payables403.97K1.48M(1.33M)506.79K388.22K
Other Working Capital(86.2K)167.52K(20.41K)2.98M(2.99M)
Other Non-Cash Items0004.55M(716.46K)
Operating Cash Flow(7.32M)(7.23M)(7.86M)(6.4M)(12.2M)
Capital Expenditures10000
Acquisitions (Net)00000
Purchases of Investments0(4.92M)(7.88M)(15.32M)(87.15M)
Sales of Investments0012.81M985.73K23.7M
Other Investing Activities00000
Investing Cash Flow0(4.92M)4.93M(14.34M)(63.45M)
Debt Repayment00000
Common Stock Issued10.93M109.34K2.07M59.4M127.71M
Common Stock Repurchased0000(35M)
Dividends Paid00000
Other Financing Activities(45.78K)(76.46K)(46.97K)(104.14K)(1.13M)
Financing Cash Flow10.88M32.87K2.03M59.29M91.57M
Effect of Forex Changes4.62K(3.48K)(16.8K)49497.27K
Net Change in Cash3.57M(12.12M)(920.11K)38.55M16.02M
Free Cash Flow(7.32M)(7.23M)(7.86M)(6.4M)(12.2M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$13.7M
+ D&A$0
+ Stock-Based Comp$4.8M
+ Deferred Tax$0
- Working Capital-$2.6M
- Other Non-Cash-$716.5K
= Operating Cash Flow-$12.2M
- Capex$0
= Free Cash Flow-$12.2M

Analysis

FY2025 free cash flow is -$12.2M. FCF conversion is 89.0% of net income. Operating cash flow was -$12.2M, with capex of $0. The largest bridge item is Stock-Based Comp at $4.8M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 12, 2026
10-QQuarterly reportNov 12, 2026
4Statement of changes in beneficial ownershipNov 4, 2026
4Statement of changes in beneficial ownershipNov 4, 2026
SC 13GSC 13G filingOct 27, 2026

Does MNPR generate free cash flow?

Monopar Therapeutics Inc. (MNPR) generated -$12.20M of free cash flow in fiscal 2025.

How much operating cash flow does MNPR produce?

Operating cash flow was -$12.20M, before capital expenditures of $0.00.